ENTITY
WuXi XDC Cayman

WuXi XDC Cayman (2268 HK)

122
Analysis
Health CareChina
WuXi XDC Cayman Inc. operates as a leading contract testing, development and manufacturing organization focused on the global antibody drug conjugates and broader bioconjugate market. The Company provides bioconjugation discovery, analytical development, intermediate and conjugation manufacturing, and other services. WuXi XDC Cayman provides its services worldwide.
more
bullishWuXi XDC Cayman
16 Aug 2023 11:01

WuXi XDC Cayman Pre-IPO - The Positives - Sales Have Surged Leading to Market Share Gains

WuXi XDC Cayman Inc (1877628D HK) is looking to raise at least US$100m in its upcoming Hong Kong IPO. In this note, we will talk about the positive...

Logo
561 Views
Share
19 Jul 2023 08:55

Porton Pharma Solutions (300363.CH) 23H1 - Performance Pressure Would Remain in 2023

Porton's weak performance will continue in 23H2. As a latecomer, its ADC CDMO business is still at early stage. When the entire sector is at bottom...

Logo
517 Views
Share
bullishWuXi XDC Cayman
18 Jul 2023 09:33

WuXi XDC Cayman Pre-IPO Tearsheet

WuXi XDC Cayman Inc (1877628D HK) is looking to raise >US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Morgan Stanley,...

Logo
604 Views
Share
bullishWuXi XDC Cayman
17 Jul 2023 08:55

Pre-IPO WuXi XDC - The Beautiful Story and the Truth Behind

How far WuXi XDC can go in the future depends on the real market space of ADC and the company's performance. But as a capital operation, good story...

Logo
619 Views
Share
x